Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $46.64M (cash outflow) rose 73.5% year over year, ahead of the +61.4% change in trailing-twelve-month net income. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at -13.1% a year.

Context

  • Net income amounted to 1115.3% of revenue in FY2025, up 43.6 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$164.25M (+50.7%) for the fiscal year ending Dec 2026, a step up from the +22.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$46.64M+10.0% QoQ
Last fiscal yearDec 2025
-$109M+22.1% YoY
LTMJun 2026
-$149.63M+61.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.5%+59.5%-14.0 pp
1 year+22.1%+50.7%+28.6 pp
3-year CAGR-13.1%+1.1%+14.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(109M) USD
Year-over-year change
-22.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's LTM Jun 2026 net income of $149.63M is the 4th largest of the 9 companies compared; the peer median is $107.64M.
  • Its year-over-year change of +61.4% is the 4th highest of 9, against a peer median of +47.3%.
  • Net income amounts to 2728.0% of revenue for TSHA, versus a peer median of 319.6%.
TSHA Competitors Peer median
Net Income for TSHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$290.01M +83.9%-11.6%330.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$209.38M -18.9%+0.2%—
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026$149.63M +61.4%-13.1%2728.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
NGNENeurogene Inc.LTM Mar 2026$98.64M +22.0%+17.9%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$66.14M +249.7%—454.9%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.06M +126.2%+0.5%3.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$41.54M +56.8%+27.7%—
Peer median (excluding TSHA) $107.64M+47.3%+9.2%319.6%

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Depreciation & Amortization492K1.17M1.37M1.25M1.15M
Deferred Income Tax00000
Stock-Based Compensation18.18M18.04M7.91M13.1M13.3M
Change in Working Capital28.67M18.52M(18.01M)(12.47M)(5.37M)
Accounts Receivables00000
Inventory00000
Accounts Payables14.49M(7.8M)(2.3M)(2.92M)(153K)
Other Working Capital14.17M26.32M(15.72M)(9.55M)(5.22M)
Other Non-Cash Items10.14M39.89M47.28M6.19M6.83M
Operating Cash Flow(117.04M)(88.39M)(73.02M)(81.23M)(93.09M)
Capital Expenditures(21.55M)(24.87M)(7.37M)(374K)(738K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(6.25M)(61K)(3.48M)11K134K
Investing Cash Flow(21.55M)(24.93M)(7.35M)(363K)(604K)
Debt Repayment39.96M0(3.45M)09.24M
Common Stock Issued(360K)53.24M140.79M76.78M265.69M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(514K)(1.15M)(947K)(96K)(337K)
Financing Cash Flow39.08M52.1M136.39M76.68M274.59M
Effect of Forex Changes00000
Net Change in Cash(99.51M)(61.22M)56.02M(4.9M)180.9M
Free Cash Flow(138.6M)(113.26M)(80.39M)(81.6M)(93.83M)

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.